PALVELLA THERAPEUTICS INC (PVLA) Stock News

USA - NASDAQ:PVLA - US6979471090 - Common Stock

93.99 USD

+11.05 (+13.32%)

Last: 11/19/2025, 2:58:31 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PVLA Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill

News Image

Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones

8 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

8 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

8 days ago - By: Benzinga - Mentions: NXGL SE UPXI SFL ...

Earnings Scheduled For November 11, 2025

13 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

13 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

14 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

14 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

15 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

15 days ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

a month ago - By: Palvella Therapeutics Inc.

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

a month ago - By: Palvella Therapeutics Inc.

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

2 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

3 months ago - By: Palvella Therapeutics Inc. - Mentions: ARQT

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

3 months ago - By: The Motley Fool

Palvella Posts Cash Gain and Trial Wins

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

3 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

4 months ago - By: Yahoo Finance - Mentions: WFC UBS MNDY CACI ...

Snap downgraded, Leidos upgraded: Wall Street's top analyst calls

4 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: Yahoo Finance

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

5 months ago - By: Palvella Therapeutics Inc.

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors